TheraRadar
← Back
Data updated: Jun 28, 2026

MACROGENICS INC

Biotech
OncologyMetabolicGastroenterology Execution: Fair

MACROGENICS INC is a biotechnology company focused on Oncology, Metabolic, Gastroenterology.

2020
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

FDA Novel Drug Designations

(2020)
1 Novel 1 Fast Track
See 1 novel approval →
2020 MARGENZA (MARGETUXIMAB-CMKB) Fast Track

MACROGENICS INC's Key Drugs

MACROGENICS INC's core commercial portfolio centers on MARGENZA, spanning Oncology and Metabolic — its most strategically important drugs approved in the last 15 years.

MARGENZA
Oncology

Breast Cancer

FCGR2B Approved 2020

MACROGENICS INC's Recent FDA Approvals

New NDA/BLA approvals for MACROGENICS INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MACROGENICS INC's Therapeutic Areas

MACROGENICS INC's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 72%
1 drugs Phase 3: 1 Phase 2: 8 Phase 1: 18
Metabolic 10%
0 drugs Phase 3: 1 Phase 1: 2
Gastroenterology 8%
0 drugs Phase 2: 1 Phase 1: 3
Infectious Disease 7%
0 drugs Phase 2: 1 Phase 1: 2
Immunology 3%
0 drugs Phase 1: 2

MACROGENICS INC Pipeline Snapshot

MACROGENICS INC has 39 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 10 Phase 2 and 27 Phase 1.

2
Phase 3
10
Phase 2
27
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • MARGENZA leads revenue
  • • Drug-level revenue analysis
View revenue breakdown →

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 1/2 completed
  • • Speed: 42 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges